Scil, Ono partner to develop Affilin therapeutics

As a part of the agreement, Scil will select and characterize Affilin candidates directed against certain targets provided by Ono.

Scil will receive funds for the research and milestone payments for research, development and commercialization, as well as royalties.

Scil Proteins’ chief business officer Henning Afflerbach said the collaboration with Ono is an important commercial milestone for Scil, which further affirms the technical and scientific concepts behind Affilin platform.

"We are pleased to have successfully implemented our fully integrated offering of providing proprietary, fully patent-protected compounds in combination with production process development and GMP manufacturing into a cutting-edge collaborative research with a leading pharmaceutical company," Afflerbach added.